DWA
TARS icon

Dorsey Wright & Associates’s Tarsus Pharmaceuticals TARS Stock Holding History

Dorsey Wright & Associates’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,289
Closed -$23.3K – 324
2023
Q2 		$23.3K Buy
+1,289
New +$20.5K 0.01% 227

Other funds holding TARS

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Dorsey Wright & Associates's TARS Position: Q3 2023 in Review

Dorsey Wright & Associates sold out of Tarsus Pharmaceuticals (TARS) in Q3 2023, closing a stake of 1,289 shares — an estimated $23.3K sold.

Dorsey Wright & Associates first reported a position in TARS in Q2 2023 and held it in 1 quarter. The position peaked at $23.3K in Q2 2023. 105 funds tracked by Wall St. Rank hold TARS as of Q3 2023.

  • Dorsey Wright & Associates reported no remaining Tarsus Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Dorsey Wright & Associates sold 1,289 Tarsus Pharmaceuticals shares in Q3 2023, an estimated $23.3K.
  • Dorsey Wright & Associates first reported a position in Tarsus Pharmaceuticals in Q2 2023 and held it in 1 quarter.
  • Dorsey Wright & Associates's Tarsus Pharmaceuticals position peaked at $23.3K in Q2 2023.
  • 105 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q3 2023.

Based on Dorsey Wright & Associates's 13F filing for Q3 2023, filed 7 Nov 2023.